Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
about
Optimal management of high-risk T1G3 bladder cancer: a decision analysisCost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.Pharmacoeconomic considerations in anticoagulant drug use.Cost effectiveness of anticoagulation in acute coronary syndromes.A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
P2860
Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cost-utility of enoxaparin com ...... stable coronary artery disease
@ast
Cost-utility of enoxaparin com ...... stable coronary artery disease
@en
Cost-utility of enoxaparin com ...... stable coronary artery disease
@nl
type
label
Cost-utility of enoxaparin com ...... stable coronary artery disease
@ast
Cost-utility of enoxaparin com ...... stable coronary artery disease
@en
Cost-utility of enoxaparin com ...... stable coronary artery disease
@nl
prefLabel
Cost-utility of enoxaparin com ...... stable coronary artery disease
@ast
Cost-utility of enoxaparin com ...... stable coronary artery disease
@en
Cost-utility of enoxaparin com ...... stable coronary artery disease
@nl
P2860
P921
P356
P1476
Cost-utility of enoxaparin com ...... stable coronary artery disease
@en
P2093
Tricia Nicholson
P2860
P2888
P356
10.1186/1471-2261-1-2
P407
P577
2001-10-15T00:00:00Z
P5875
P6179
1025421251